Mathews Marlon S, Sharma Jitendra, Snyder Kenneth V, Natarajan Sabareesh K, Siddiqui Adnan H, Hopkins L Nelson, Levy Elad I
Department of Neurosurgery, School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, USA.
Neurosurgery. 2009 Nov;65(5):860-5; discussion 865. doi: 10.1227/01.NEU.0000358953.19069.E5.
This study assesses the safety, effectiveness, and practicality of endovascular therapy for ischemic stroke within the first 3 hours of symptom onset.
A retrospective chart review (January 2000-July 2008) was performed of 94 consecutive patients who had endovascular therapy within 3 hours after acute ischemic stroke onset. Endovascular therapy was administered in patients in whom intravenous (IV) thrombolysis failed or was contraindicated. Outcome measures analyzed were recanalization rate, intracranial hemorrhage (ICH) rate, procedural complications, modified Rankin Scale score, National Institutes of Health Stroke Scale (NIHSS) score, and mortality rate.
The study included 41 male and 53 female patients with a mean age of 68 years (age range, 13-98 years). The mean NIHSS score at the time of admission was 14.7. Eight-three patients had anterior circulation ischemic events, and 11 had posterior circulation ischemic events. The cause was determined to be arterioembolic in 21 patients (22%), cardioembolic in 45 (48%), arterial dissection in 2, left-to-right cardiac shunt in 1, and unknown in 25 (27%). Endovascular interventions included intra-arterial (IA) pharmacological thrombolysis (n = 44), mechanical thrombolysis (Merci Retrieval System, intracranial or extracranial stent, microwire) (n = 79), and intracranial or extracranial angioplasty (n = 32) in various combinations. The mean time from stroke onset to angiogram was 72 minutes. Thirteen patients received a half dose (n = 8) or full dose (n = 5) of IV thrombolysis (tissue plasminogen activator [tPA]) in conjunction with endovascular therapy. Twenty-two patients received IA or IV adjunctive glycoprotein IIb/IIIa inhibitor (eptifibatide). Partial-to-complete recanalization (Thrombolysis in Myocardial Infarction scale score of 2 or 3) was achieved in 62 of 89 of patients (70%) presenting with significant occlusion (Thrombolysis in Myocardial Infarction scale score of 0 or 1). Postprocedure symptomatic ICH occurred in 5 patients (5.3%), which was purely subarachnoid hemorrhage in 3 patients. Of these, 2 received IA tPA in conjunction with Merci Retrieval System passes; the others each received IA tPA, mechanical thrombectomy (guidewire), or extracranial angioplasty. The total mortality rate including procedural mortality, progression of disease, and other comorbidities was 26.6%. Sixteen patients (17%) were discharged home, 49 (52%) to rehabilitation, and 4 (4%) to long-term care facilities. Overall, 36.7% had a modified Rankin Scale score of 2 or less at discharge. The mean NIHSS score at discharge was 6.5, representing an overall 8-point improvement on the NIHSS.
Endovascular therapy within the first 3 hours of stroke symptom onset in patients in whom IV tPA therapy is contraindicated or fails is safe, effective, and practical. The risk of symptomatic ICH is low and should be viewed relative to the poor prognosis in this group of patients.
本研究评估症状发作后3小时内对缺血性卒中进行血管内治疗的安全性、有效性和实用性。
对94例急性缺血性卒中发作后3小时内接受血管内治疗的连续患者进行回顾性病历审查(2000年1月至2008年7月)。血管内治疗应用于静脉溶栓失败或有禁忌证的患者。分析的结局指标包括再通率、颅内出血(ICH)率、操作并发症、改良Rankin量表评分、美国国立卫生研究院卒中量表(NIHSS)评分和死亡率。
该研究纳入41例男性和53例女性患者,平均年龄68岁(年龄范围13 - 98岁)。入院时NIHSS平均评分为14.7。83例患者发生前循环缺血事件,11例发生后循环缺血事件。病因确定为动脉栓塞21例(22%),心源性栓塞45例(48%),动脉夹层2例,左向右心脏分流1例,原因不明25例(27%)。血管内干预措施包括动脉内(IA)药物溶栓(n = 44)、机械溶栓(Merci取栓系统、颅内或颅外支架、微导丝)(n = 79)以及颅内或颅外血管成形术(n = 32)的各种组合。从卒中发作到血管造影的平均时间为72分钟。13例患者在接受血管内治疗的同时接受了半量(n = 8)或全量(n = 5)静脉溶栓(组织型纤溶酶原激活剂[tPA])。22例患者接受了IA或静脉辅助糖蛋白IIb/IIIa抑制剂(依替巴肽)。89例存在严重闭塞(心肌梗死溶栓量表评分0或1)的患者中,62例(70%)实现了部分至完全再通(心肌梗死溶栓量表评分2或3)。术后有症状性ICH发生在5例患者(5.3%)中,其中3例为单纯蛛网膜下腔出血。其中,2例在接受IA tPA联合Merci取栓系统操作时发生;其他患者分别接受了IA tPA、机械取栓(导丝)或颅外血管成形术。包括操作相关死亡率、疾病进展和其他合并症在内的总死亡率为26.6%。16例患者(17%)出院回家,49例(52%)前往康复机构,4例(4%)前往长期护理机构。总体而言,36.7%的患者出院时改良Rankin量表评分为2或更低。出院时NIHSS平均评分为6.5,表明NIHSS总体改善了8分。
对于IV tPA治疗禁忌或失败的患者,在卒中症状发作后3小时内进行血管内治疗是安全、有效且实用的。有症状性ICH的风险较低,应相对于该组患者的不良预后进行权衡。